Coronado Biosciences Inc  

(Public, NASDAQ:CNDO)   Watch this stock  
Find more results for cndo
1.62
-0.01 (-0.61%)
After Hours: 1.62 0.00 (0.00%)
Jul 28, 5:19PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.60 - 1.65
52 week 1.25 - 10.20
Open 1.62
Vol / Avg. 190,453.00/385,513.00
Mkt cap 71.77M
P/E     -
Div/yield     -
EPS -1.10
Shares 44.31M
Beta     -
Inst. own 26%
Aug 4, 2014
Q2 2014 Coronado Biosciences Inc Earnings Release (Estimated) Add to calendar
Jun 16, 2014
Coronado Biosciences Inc Annual Shareholder Meeting
May 14, 2014
Coronado Biosciences Inc at Bank of America Merrill Lynch Health Care Conference
May 12, 2014
Q1 2014 Coronado Biosciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -30.24% -52.49%
Return on average equity -37.71% -71.93%
Employees 14 -
CDP Score - -

Address

24 NEW ENGLAND EXECUTIVE PARK
BURLINGTON, MA 01803
United States - Map
+1-781-6524500 (Phone)
+1-781-4597788 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Coronado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. The Company�s two principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201 (TSO) a biologic comprising of the microscopic eggs of the porcine whipworm, for the treatment of autoimmune diseases, such as Crohn�s disease (Crohn�s), ulcerative colitis (UC) and multiple sclerosis (MS), and CNDO-109, a compound that activates natural killer (NK) cells of the immune system to seek and destroy cancer cells, for the treatment of acute myeloid leukemia (AML). In January 2011, the Company acquired the OvaMed GmbH License.

Officers and directors

Lindsay A. Rosenwald M.D. Chairman of the Board, President, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Eric K. Rowinsky M.D. Vice Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Lucy Lu M.D. Chief Financial Officer, Executive Vice President
Age: 38
Bio & Compensation  - Reuters
Michael S. Weiss Executive Vice Chairman - Strategic Development
Age: 48
Bio & Compensation  - Reuters
George Avgerinos Ph.D. Senior Vice President - Biologics Operations
Bio & Compensation  - Reuters
Malcolm Hoenlein Ph.D. Director
Age: 70
Bio & Compensation  - Reuters
David J. Barrett Independent Director
Age: 60
Bio & Compensation  - Reuters
Jimmie Harvey Jr., M.D. Independent Director
Age: 61
Bio & Compensation  - Reuters
J. Jay Lobell J.D. Independent Director
Age: 50
Bio & Compensation  - Reuters